SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Quick Stats
Jun 05, 202658.9
AI Score
HOLD0.74
Volume Ratio
May 19, 2026
Next Earnings
17
+ve Days (30d)
12
-ve Days (30d)
SLS Stock Summary
Last updated Jun 05, 2026
SLS is currently trading at $8.23, positioned above its 200-day moving average of $3.64, indicating a long-term uptrend. The stock has a 52-week range of $1.39 to $9.51.
Technical Analysis: The 50-day moving average stands at $5.92, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 57.199, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.275, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates SLS at 58.9/100 with a HOLD recommendation.
SLS (SELLAS Life Sciences Group, Inc. Common Stock) Indicators
Last updated Jun 05, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 57.199 |
| CMF (20) | 0.275 |
| ROC (10) | 8.862 |
| ADX (14) | 36.175 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.849 |
| AROONOSC (14) | 50.0 |
| WILLAMS %R (14) | -48.12 |
| MFI (14) | 60.178 |
SLS Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
SLS Price vs Max Options Open Interest
SLS Max Change In Options Open Interest
SLS Options - Sort by Max open Interest (near term)
6th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SLS Daily Out of Money Options - Sort by Max open Interest (near term)
6th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SLS Daily In the Money Options - Sort by Max open Interest (near term)
6th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SLS Most Active Options by Volume(near term)
6th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SELLAS Life Sciences Group, Inc. Common Stock is above both 50 Day and 200 Day SMA which is considered Bullish.
SLS Moving Averages Analysis
SELLAS Life Sciences Group, Inc. Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jun 05, 2026
SELLAS Life Sciences Group, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jun 05, 2026
SLS (SELLAS Life Sciences Group, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jun 05, 2026
| Days | MA |
|---|---|
| 10 | 8.58 |
| 20 | 7.69 |
| 30 | 6.75 |
| 50 | 5.92 |
| 100 | 5.23 |
| 200 | 3.64 |
SLS Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 1.8 billion |
| Earnings/Share ($) | -0.23 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.21 |
| EPS Estimate Next Year ($) | -0.15 |
| WallStreet Target Price ($) | 10 |
| Most Recent Quarter |
Sellas Corporation (SLS) investors are discussing the possibility of the company selling exclusive rights to Merck for Keytruda for $15 billion in upfront cash. This move could potentially benefit both companies, with Merck securing a shield to evergreen their Keytruda empire and Sellas becoming a multi-billion-dollar independent royalty engine. Investors are urging Sellas CEO Dr. Stergiou to consider this option and potentially cut ties with Stifel if they continue to push for cheap financing or buyouts. Additionally, there is speculation about a potential press release from Sellas this morning regarding their GPS therapy.
Updated 2026-06-01 08:00:01